Cardiovascular disease risk assessment for primary prevention: Our approach
- Peter WF Wilson, MD
Peter WF Wilson, MD
- Professor of Medicine
- Emory University School of Medicine
- Section Editor
- Bernard J Gersh, MB, ChB, DPhil, FRCP, MACC
Bernard J Gersh, MB, ChB, DPhil, FRCP, MACC
- Editor-in-Chief — Cardiovascular Medicine
- Section Editor — Coronary Heart Disease; Myopericardial Disease
- Professor of Medicine
- Mayo Clinic College of Medicine
Atherosclerotic cardiovascular disease (CVD) is common in the general population, affecting the majority of adults past the age of 60 years. As a diagnostic category, CVD includes four major areas:
●Coronary heart disease (CHD) manifested by fatal or nonfatal myocardial infarction (MI), angina pectoris, and/or heart failure (HF)
●Cerebrovascular disease manifested by fatal or nonfatal stroke and transient ischemic attack
●Peripheral artery disease manifested by intermittent claudication and critical limb ischemia
●Aortic atherosclerosis and thoracic or abdominal aortic aneurysmTo continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information on subscription options, click below on the option that best describes you:
- Lloyd-Jones DM, Larson MG, Beiser A, Levy D. Lifetime risk of developing coronary heart disease. Lancet 1999; 353:89.
- Lloyd-Jones DM, Leip EP, Larson MG, et al. Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age. Circulation 2006; 113:791.
- Graham I, Atar D, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited experts). Eur Heart J 2007; 28:2375.
- Goff DC Jr, Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014; 129:S49.
- Kavousi M, Leening MJ, Nanchen D, et al. Comparison of application of the ACC/AHA guidelines, Adult Treatment Panel III guidelines, and European Society of Cardiology guidelines for cardiovascular disease prevention in a European cohort. JAMA 2014; 311:1416.
- DeFilippis AP, Young R, Carrubba CJ, et al. An analysis of calibration and discrimination among multiple cardiovascular risk scores in a modern multiethnic cohort. Ann Intern Med 2015; 162:266.
- Bazo-Alvarez JC, Quispe R, Peralta F, et al. Agreement Between Cardiovascular Disease Risk Scores in Resource-Limited Settings: Evidence from 5 Peruvian Sites. Crit Pathw Cardiol 2015; 14:74.
- JBS3 Board. Joint British Societies' consensus recommendations for the prevention of cardiovascular disease (JBS3). Heart 2014; 100 Suppl 2:ii1.
- Berry JD, Dyer A, Cai X, et al. Lifetime risks of cardiovascular disease. N Engl J Med 2012; 366:321.
- Berry JD, Liu K, Folsom AR, et al. Prevalence and progression of subclinical atherosclerosis in younger adults with low short-term but high lifetime estimated risk for cardiovascular disease: the coronary artery risk development in young adults study and multi-ethnic study of atherosclerosis. Circulation 2009; 119:382.
- Greenland P. British and American prevention guidelines: different committees, same science, considerable agreement. Heart 2014; 100:678.
- OUR APPROACH TO CVD RISK ASSESSMENT
- WHO SHOULD UNDERGO ESTIMATION OF CVD RISK?
- HOW TO ASSESS CVD RISK
- Identify risk factors
- Estimate CVD risk using a risk calculator
- - Choosing a risk calculator
- - Lifetime risk
- - 10-year risk versus 30-year (lifetime) risk
- Special populations
- - Patients under 40 years of age
- - Patients over 79 years of age
- HOW OFTEN SHOULD CVD RISK BE REASSESSED?
- IMPLICATIONS OF ESTIMATED CVD RISK
- Who needs primary prevention therapy?
- Do first degree relatives of high-risk patients require screening?
- Can primary prevention therapy be discontinued?
- SUMMARY AND RECOMMENDATIONS